Marlborough, Massachusetts – October 28, 2019 –Cytiva is launching KUBio™ box, a fully-integrated, flexible, and adaptable biomanufacturing environment to accelerate the production of viral vector-based gene therapies. The latest addition to the KUBio modular bioprocessing portfolio, KUBio box is expected to speed gene therapies to market and contribute to increased capacity in the viral vector area.
Photo: KUBio box for viral vectors inside a shell building
Gene therapies are on the rise in the treatment of a wide range of diseases including cancer. Growing at a compound annual growth rate (CAGR) of 33.3% from 2017 to 2023, the gene therapy market is projected to reach $4.4 billion by 20231. With more than 700 cell and gene therapies currently in clinical trials, demand exceeds supply of viral vectors, used in approximately 70% of these therapies under trial. Current market indicators predict that the viral vector manufacturing market will hit $816 million by 20232.
Olivier Loeillot, General Manager for BioProcess, Cytiva, says: “Rapidly adding capacity accelerates the development of novel drugs and enhances the availability of personalized medicines. With KUBio box, we are leveraging our expertise in the monoclonal antibody space to provide biomanufacturers with faster and more cost-effective solutions for advancing next-generation therapeutics.”
The first KUBio box on the market is developed in collaboration with Germfree, a Florida-based biotech company globally recognized for its pioneering manufacturing of process ready cleanroom facilities. KUBio box features a Germfree biosafety level 2 (BSL-2) modular bioprocessing environment based on Cytiva’s proprietary design and equipped with the FlexFactory™ single-use biomanufacturing platform, tailored for the production of viral vectors.
Carol Houts, Germfree’s Vice President Quality and Business Strategy says: “Viral vector manufacturing is a strong differentiator for gene therapy companies with products designated for accelerated pathways to commercialization. However, capacity constraints often impede this path. KUBio box provides process-ready solutions that promote product development and production-readiness for delivering viral vector-based gene therapies to patients.”
KUBio box supports up to 200-liter scale manufacturing adapted to Good Manufacturing Practice (GMP) standards and is designed to fit into repurposed or retrofitted existing spaces, as well as new facilities. The new modular environment allows for future expansion at different production scales and product technologies. Cytiva provides end-to-end bioprocessing services, including technical process development, qualification and lifecycle support.
Cytiva launched the first off-the-shelf KUBio modular facility in 2012 for the biomanufacturing of monoclonal antibodies. The KUBio portfolio has expanded over the years to support the production of vaccines and viral vectors as well. Four KUBio facilities have been deployed globally by Pfizer, Lonza, JHL, and BeiGene for the manufacturing of biopharmaceuticals.
KUBio box for viral vectors is commercially available now.
Cytiva transforms the global ecosystem of biomanufacturing through education and collaborations:
- In 2019, NIBRT announced a collaboration with Cytiva to deliver global training in single-use technology, including cell and gene therapy.
- In 2019, Bayer broke ground on a site in California to make biologic therapies using Cytiva’s FlexFactory biomanufacturing platform.
- In 2019, BeiGene opened a KUBio biomanufacturing facility in Guangzhou China.
- In 2018, Lonza announced an agreement with Cytiva, under which Cytiva will develop a biologics center featuring a KUBio biomanufacturing facility. The center is expected to be operational in 2020.
- In 2016, Pfizer broke ground to establish a biotechnology center in China based on Cytiva’ KUBio biomanufacturing platform.
1 Bloomberg (February 2019) At 33.3% Soaring CAGR, Gene Therapy Market to Exhibit $4,402 Million by 2023
2 Cision (August 2018) Viral Vector Manufacturing Market Worth $815.8 Million by 2023